However, in our cohort, FLT3-ITD was identified in only one patient with AML (1/7), suggesting a deficiency in the FLT3 pathway in the leukemogenesis of the BRAF-mutated patients with AML. This evidence concerns the gene FLT3 and acute myeloid leukemia.